Yang Gao

This study identifies an early neutrophil interferon program that predicts resistance to anti-PD1 therapy and limits durable anti-tumor immunity.

This paper shows that combining MERTK inhibition with cyclophosphamide enhances anti-tumor immunity in basal-like TNBC by reprogramming macrophages and promoting CD4 T cell responses.

This paper identifies AADAT as a metabolic immune checkpoint in TNBC that promotes immune evasion by regulating malate and CoQ10, and shows that malate supplementation can reverse immunotherapy resistance.

The paper analyzes bone metastases from six cancer types using single-cell RNA-seq to identify three immune archetypes and their mechanisms of bone colonization.

Zotatifin targets EIF4A to suppress TNBC by inhibiting Sox4, inducing interferon response, and reprogramming the tumor immune microenvironment, synergizing with chemotherapy.